A Phase 2 Trial Investigating the Addition of Pacritinib to a Hypomethylating Agent as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant in Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms

This phase II trial tests if adding pacritinib to standard of care azacitidine or decitabine increases the number of patients able to proceed to hematopoietic stem cell transplantation (bridging) for patients with accelerated and blast phase myeloproliferative neoplasms. Pacritinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Azacitidine and decitabine are in a class of medications called hypomethylation agents. They work by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Adding pacritinib to standard of care azacitidine or decitabine may increase the number of patients able to proceed to hematopoietic stem cell transplantation for patients with accelerated and blast phase myeloproliferative neoplasms.

开始日期2026-02-01

申办/合作机构

University of Washington

[+1]

NCT07148180

/ Recruiting临床1/2期IIT

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

The purpose of this research study is to test the safety and efficacy of a new drug combination with three agents, azacitidine, venetoclax and tagraxofusp. Leftover (residual) leukemia disease that is not visible by eye can be increase the chance of disease recurrence. This research study is to determine if the combination therapy can safely help to control residual Acute Myeloid Leukemia (AML) and to prevent disease recurrence.
The names of the study drugs involved in this study are:
* Tagraxofusp (a type of CD123-directed cytotoxin)
* Azacitidine (a type of standard of care cytidine nucleoside analog)
* Venetoclax (a type of standard of care BCL-2 inhibitor)

开始日期2026-02-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT07177079

/ Not yet recruiting临床1期IIT

High-dose Ascorbate (HDA) in Combination With Azacitidine and Venetoclax (Aza/Ven) in Newly Diagnosed Acute Myeloid Leukemia (AML)

This is a randomized, open-label, Phase I clinical study with expansion. It will assess the safety and efficacy of high-dose ascorbate administered concomitantly with azacitidine and venetoclax in newly diagnosed AML.

开始日期2025-12-31

申办/合作机构

University of Iowa

100 项与阿扎胞苷相关的临床结果

登录后查看更多信息

100 项与阿扎胞苷相关的转化医学

登录后查看更多信息

100 项与阿扎胞苷相关的专利（医药）

登录后查看更多信息

8,254

项与阿扎胞苷相关的文献（医药）

2025-12-31·ANNALS OF MEDICINE

Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis

Article

作者: Zheng, Jing ; Wu, Yong ; Wu, Lanlan ; Chen, Yi ; Zhou, Jiayi ; Wu, Zhengjun ; Cai, Ruyu ; Wang, Zhengyang

OBJECTIVE:

This investigation aim to analyze the clinical features and therapeutic outcomes of elderly patients with acute myeloid leukemia (AML).

METHOD:

We conducted a retrospective analysis of the clinical and cytogenetic profiles of patients aged 60 years and older diagnosed with AML at the Fujian Medical University Union Hospital from 2016 to 2024.

RESULTS:

Our study cohort included 846 patients, with a median age of 67 years. The median duration of response (DOR) was 15.8 months, with 1-year, 3-year, and 5-year DOR rates of 55.3%, 23.4%, and 13.1%, respectively. The median overall survival (OS) was 21.8 months, with corresponding 1-year, 3-year, and 5-year OS rates of 58.7%, 41.2%, and 30.0%. Patients who received the azacitidine and venetoclax treatment protocol exhibited a complete remission (CR) rate of 57.1% and a minimal residual disease (MRD) - negative rate of 34.1%. These rates were comparable to the 59.2% CR rate and 39.4% MRD-negative rate observed in patients treated with intensive chemotherapy, and were superior to those with other low-intensity regimens. Compared to the treatment outcomes achieved at our center prior to 2016, when chemotherapy was the predominant treatment modality, which were characterized by a CR rate of 42.7%, a median OS of 9.2 months, and a mere 5-year OS rate of 13.5%, the remission rate and long-term survival of elderly patients with AML have been remarkable improved.

CONCLUSION:

The integration of hypomethylating agents and venetoclax into the treatment paradigm for elderly patients with AML has significantly enhanced survival rates.

2025-12-31·Hematology

Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML

Article

作者: Chen, Yu ; Zhu, Yi-yan ; Liu, Yi-zi ; Hou, Chun-xiao ; Zhang, Zhi-yu ; Chen, Su-ning ; Wang, Qian ; Zhang, Feng-hong

OBJECTIVE:

Hematological malignancies often involve chromosomal translocations and fusion genes that drive disease progression. While MTCP1 is well-known in T-cell prolymphocytic leukemia (T-PLL), its role in myeloid neoplasms is less understood. This report presents the first identification of the t(X;1)(q28;q21) translocation leading to the GATAD2B::MTCP1 fusion in acute myeloid leukemia (AML) transformed from chronic myelomonocytic leukemia (CMML).

METHODS:

The karyotypes were described according to the International System for Human Cytogenetic Nomenclature 2009. We performed targeted next-generation sequencing (NGS) on a panel of 172 genes commonly mutated in hematological malignancies (Supplemental Table 1), using an Illumina platform. RNA sequencing was conducted on total RNA extracted from bone marrow, also using the Illumina platform. The GATAD2B::MTCP1 fusion gene was confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and Sanger sequencing, with specific primers for the fusion transcript (GATAD2B-F: CCTCTTTTTTTCGACGCC; MTCP1-R: ACTGAGCACAACACTTACGC).

RESULTS:

The GATAD2B::MTCP1 fusion results from a breakpoint on 1q21 within GATAD2B exon 1 and Xq28 within MTCP1 exon 2. The patient with the GATAD2B::MTCP1 fusion exhibited disease progression from CMML to AML. Despite achieving initial remission with venetoclax-based therapy and allo-HSCT, the patient relapsed and died.

CONCLUSIONS:

We propose that the GATAD2B::MTCP1 fusion upregulates MTCP1 expression rather than generating a fusion protein, thereby contributing to transformation and relapse in AML. Further investigations are needed to elucidate the precise role of this fusion event in myeloid malignancies.

2025-12-31·Epigenetics

CpG island demethylation and recruitment of SP1 to the promoter region regulates human thymic stromal lymphopoietin expression

Article

作者: Surjit, Milan ; Ganti, Krishna Priya

Thymic Stromal Lymphopoietin (TSLP), an immunomodulatory cytokine, plays a pivotal role in the development and progression of atopic and allergic diseases. Atopy follows familial inheritance, and genome-wide studies have shown association of atopy with TSLP polymorphisms. Here, we analysed the conserved transcriptional regulatory elements in the human TSLP promoter, which revealed the presence of three CpG islands. Demethylation of the CpG island using 5-azacytidine or siRNA-mediated knockdown of DNA methyl transferases significantly upregulated TSLP expression. Sequence analysis revealed the presence of two overlapping SP1 transcription factor DNA-binding sites (DBSs), between -1494 and -1510 nucleotides on the human TSLP promoter. Further experiments showed that demethylation of the CpG island enables the binding of SP1 to its cognate DBS present on the TSLP promoter, resulting in its transcriptional activation. Moreover, retinoic acid-induced transcription of human TSLP was associated with CpG island demethylation and SP1 binding to the TSLP promoter. These findings unravel a distinct mechanism of transcriptional regulation of the human TSLP gene and suggest possible epigenetic regulation of TSLP expression in modulating atopic and allergic disease severity in different individuals.

1,370

项与阿扎胞苷相关的新闻（医药）

2025-11-06

·GlobeNewswire-Health Care

Kura Oncology and Kyowa Kirin Announce Presentations of Ziftomenib Ven/Aza Combination Data in Frontline and Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia at 2025 ASH Annual Meeting

– Data to be featured in two oral presentations on December 8, 2025 – – Broad development program assesses ziftomenib across diverse AML segments and treatment paradigms to inform appropriate use – SAN DIEGO and TOKYO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced that results from the KOMET-007 combination trial of ziftomenib, a once-daily, oral investigational menin inhibitor, will be featured in two oral presentations at the upcoming American Society of Hematology (ASH) 2025 Annual Meeting, on December 8, 2025 in Orlando, FL. KOMET-007 is an ongoing Phase 1a/b dose-escalation/expansion study of ziftomenib in combination with standard-of-care chemotherapies in adults with NPM1-mutated (NPM1-m) or KMT2A-rearranged (KMT2A-r) acute myeloid leukemia (AML). The combination data presented at ASH will include data in both newly diagnosed adults with NPM1-m AML and updated data in adults with relapsed or refractory NPM1-m or KMT2A-r AML treated with ziftomenib in combination with the non-intensive chemotherapy regimen of venetoclax and azacitidine (ven/aza). The two ziftomenib abstracts are based on an earlier data cutoff of June 2025, in line with ASH submission timelines. The oral presentations at ASH will include more mature data, including additional response-evaluable patients, longer follow-up and expanded safety summaries. “At ASH 2025, we look forward to sharing data evaluating ziftomenib with venetoclax / azacitidine in both the newly diagnosed and relapsed/refractory AML settings,” said Mollie Leoni, M.D., Chief Medical Officer of Kura Oncology. “These trials are part of a comprehensive and focused clinical development plan designed to understand how menin inhibition can benefit the greatest number of patients in need. We expect to continue generating data from the combination of ziftomenib with commonly used treatment backbones across multiple trials, including the KOMET-017 Phase 3 trial. The emerging profile from this effort gives us confidence that ziftomenib as monotherapy and in combination represents a meaningful step forward for patients if these findings are confirmed.” ASH Presentations: Ziftomenib in Combination with Venetoclax and Azacitidine in Relapsed / Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Updated Phase 1a/b safety and clinical activity results from KOMET-007Session 616. Menin inhibitors and FLT3 inhibitors in AMLMonday, December 8, 2025; 10:45-11:00 AM ETChapin Theater (320)Oral #764 Ziftomenib in Combination with Venetoclax and Azacitidine in Newly Diagnosed NPM1-m Acute Myeloid Leukemia: Phase 1b Results from KOMET-007Session 616. Menin inhibitors and FLT3 inhibitors in AMLMonday, December 8, 2025; 11:15-11:30 AM ETChapin Theater (320)Oral #766 Copies of the presentations will be available on Kura's website at www.kuraoncology.com/pipeline/publications/ following presentation at the meeting. About Kura OncologyKura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura is developing ziftomenib, a menin inhibitor targeting certain genetic drivers of acute myeloid leukemias, and continues to pioneer advancements in menin inhibition for acute leukemias and solid tumors and in farnesyl transferase inhibition to address mechanisms of adaptive and innate resistance in the treatment of solid tumors. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn. About Kyowa KirinKyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin’s values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at www.kyowakirin.com. Kura Forward-Looking StatementsThis news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the expected timing and presentation of results and data from the KOMET-007 clinical trial; the expectation of continued data generation from the combination of ziftomenib with commonly used treatment backbones across multiple trials, including the KOMET-017 trials; and the therapeutic potential of ziftomenib as a monotherapy and in combination with commonly used treatment backbones;. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early clinical trials do not demonstrate safety and/or efficacy in later clinical trials; uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies; risks associated with reliance on third parties to successfully conduct clinical trials; the risk that the collaboration with Kyowa Kirin is unsuccessful; and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura's periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contact Investors and Media:Greg Mann858-987-4046gmann@kuraoncology.com Kyowa Kirin Contacts Investors:Ryohei Kawai ir@kyowakirin.com Media, Global:Nobuyuki Manita media@kyowakirin.com

临床结果ASH会议

2025-11-05

·ioncology

2025 ASH大会摘要公布！近百篇中国学者研究入选口头报告，唱响中国最强音！

编者按第67届美国血液学会（ASH）年会将于2025年12月6～9日在美国奥兰多盛大举行。作为全球血液学领域规模最大、学术影响力最强、内容最全面的国际盛会之一，每年都会吸引来自世界各地的数万名专家学者，共同分享血液学领域的最新进展与突破性研究成果。当地时间11月3日，大会官网公布了入选研究摘要，令人振奋的是，由中国学者主导的近百篇研究成功入选口头报告（Oral），再创历史新高！这些成果不仅代表了血液学前沿探索的最新高度，也充分展现了中国科研力量在国际舞台上的快速崛起与卓越贡献。《肿瘤瞭望-血液时讯》对此汇总整理，邀您一同领略中国血液学专家的创新实力与非凡风采。恶性血液疾病 ASH 2025 摘要号：abs25-11291 英文标题：Cdk6 targeting reverses leukemia in germline cebpa Q83X AML mouse model with CMP-origin transformation 中文标题：在具有CMP起源转化的生殖系cebpa Q83X AML小鼠模型中，靶向Cdk6可逆转白血病讲者及单位：Lili Pan，福建医科大学附属协和医院摘要号：abs25-1496 英文标题：Clonal timing of FLT3-ITD dictates evolutionary trajectory and phenotypic heterogeneity in acute myeloid leukemia 中文标题：FLT3-ITD克隆出现时间决定了急性髓系白血病的进化轨迹和表型异质性讲者及单位：Xu-Dong He，中国科学院北京基因组研究所（国家生物信息中心）摘要号：abs25-4703 英文标题：Targeting CPNE8 suppresses HOXA9-dependent AML progression and overcomes chemotherapy resistance 中文标题：靶向 CPNE8 抑制 HOXA9 依赖性 AML 进展并克服化疗耐药讲者及单位：Wenjing Shu，上海交通大学医学院附属瑞金医院摘要号：abs25-10483 英文标题：Long-acting GM-CSF-based drug conjugate effectively targets leukemia stem cells in Acute Myeloid Leukemia with limited toxicity 中文标题：长效GM-CSF为基础的药物偶联物在急性髓系白血病中有效靶向白血病干细胞且毒性有限讲者及单位：Zhizhuang Zhao，中山大学附属第七医院摘要号：abs25-9800 英文标题：Comprehensive profiling of highly heterogeneous FLT3-ITD variants reveals distinct drug response patterns in AML 中文标题：对高度异质性FLT3-ITD变异体的全面分析揭示了急性髓系白血病中不同的药物反应模式讲者及单位：Zhenyi Yi，中国科学院北京基因组研究所（国家生物信息中心）摘要号：abs25-9173 英文标题：Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia 中文标题：MK-1045（一种新型 CD19xCD3 T 细胞衔接器）治疗复发或难治性 B 细胞急性淋巴细胞白血病成年患者的 1b/2 期研究的最新结果讲者及单位：王迎，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-7898 英文标题：TCF3::hlf-positive b-ALL: Largest cohort study to date reveals unique molecular landscape and treatment challenges 中文标题：TCF3::HLF 阳性 B-ALL：迄今为止最大队列研究揭示独特的分子景观和治疗挑战讲者及单位：Xue Chen，河北燕达陆道培医院摘要号：abs25-2668 英文标题：Outcomes of patients with relapsed/refractory FLT3mut+ Acute Myeloid Leukemia who resumed gilteritinib therapy after HSCT: Post hoc analysis from the ADMIRAL and COMMODORE trials 中文标题：接受 HSCT 后恢复吉瑞替尼治疗的复发/难治性 FLT3 突变阳性急性髓系白血病患者的结局：来自 ADMIRAL 和 COMMODORE 试验的事后分析讲者及单位：王建祥，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-9289 英文标题：Venetoclax-based regimens versus intensive chemotherapy in fit older adults with newly diagnosed acute myeloid leukemia (AML)：a multicenter, prospective, randomized phase II trial 中文标题：维奈克拉联合方案与强化化疗在新诊断急性髓系白血病（AML）的fit老年患者中的对比：一项多中心、前瞻性、随机II期试验讲者及单位：Qiuyun Fang，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-1928 英文标题：Efficacy and safety of azacitidine plus low-dose dasatinib maintenance therapy for patients with intermediate and high-risk acute myeloid leukemia: A prospective, randomized, phase Ⅱ clinical trial 中文标题：阿扎胞苷联合低剂量达沙替尼维持治疗中危和高危急性髓系白血病患者的疗效和安全性：一项前瞻性、随机的II期临床试验讲者及单位：Xiao Tang，兰州大学第一医院摘要号：abs25-3403 英文标题：Prospective evaluation of venetoclax combined with CLAG regimen in relapsed/refractory acute myeloid leukemia: A multicenter, randomized controlled, open-lable, phase II Trial 中文标题：维奈克拉联合CLAG方案治疗复发/难治性急性髓系白血病的前瞻性评估：一项多中心、随机对照、开放标签的II期试验讲者及单位：Guopan Yu，南方医科大学南方医院摘要号：abs25-1985 英文标题：Machine learning-based novel surfaceome classification system for acute myeloid leukemia 中文标题：基于机器学习的新型表面组分类系统用于急性髓系白血病讲者及单位：Heye Yu，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-13406 英文标题：FLT3/ITD-driven noncanonical STAT1 S727 phosphorylation upregulates CD276, mediating CD8positive- T cell exhaustion and immune evasion in AML 中文标题：FLT3/ITD驱动的非典型STAT1 S727磷酸化上调CD276，介导急性髓系白血病（AML）中CD8阳性T细胞耗竭和免疫逃逸讲者及单位：梁洋，中山大学肿瘤防治中心摘要号：abs25-13097 英文标题：Vag regimen drives immune reprogramming and superior remission in older/unfit AML patients 中文标题：VAG方案推动老年/体弱急性髓系白血病（AML）患者的免疫重编程和更优的缓解效果讲者及单位：Yingying Huo，首都医科大学附属北京朝阳医院摘要号：abs25-7939 英文标题：Efficacy and safety of rocbrutinib, the fourth generation bruton's tyrosine kinase inhibitor, in patients with BTK inhibitor pre-treated relapsed or refractory Mantle Cell Lymphoma: Results from a Phase II rock-1 trial 中文标题：第四代布鲁顿酪氨酸激酶抑制剂Rocbrutinib在经BTK抑制剂预治疗的复发或难治性套细胞淋巴瘤患者中的疗效和安全性：来自II期ROCK-1试验的结果讲者及单位：宋玉琴，北京大学肿瘤医院摘要号：abs25-10744 英文标题：Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients: High remission rates even in prior BTKi-refractory patients 中文标题：Mesutoclax单药治疗复发/难治性套细胞淋巴瘤患者的疗效和耐受性：即使在既往BTKi耐药患者中也具有较高的缓解率讲者及单位：周可树，河南省肿瘤医院摘要号：abs25-7351 英文标题：Organ-based classification and risk-stratified outcomes in 568 east Asian patients with chronic active epstein-barr virus infection: A multicenter retrospective cohort study 中文标题：基于器官的分类和风险分层结局：一项针对568例慢性活动性EB病毒感染东亚患者的多中心回顾性队列研究讲者及单位：Xinran Wang，华中科技大学同济医学院附属同济医院摘要号：abs25-11418 英文标题：A prospective clinical study on the combination of anti-PD1 monoclonal antibody with lenalidomide and azacitidine for the treatment of relapsed/refractory peripheral T-cell lymphoma 中文标题：一项关于抗PD-1单克隆抗体联合来那度胺和阿扎胞苷治疗复发/难治性外周T细胞淋巴瘤的前瞻性临床研究讲者及单位：Ting Xu，苏州大学附属第一医院摘要号：abs25-8955 英文标题：Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study 中文标题：米托蒽醌脂质体与西达本胺治疗复发/难治性外周T细胞淋巴瘤：一项多中心、前瞻性、随机III期研究的最终分析讲者及单位：黄慧强，中山大学肿瘤防治中心摘要号：abs25-418 英文标题：Zanubrutinib, rituximab, and high-dose methotrexate as first-line treatment in newly diagnosed primary central nervous system lymphoma （zana）: A prospective, single-arm study 中文标题：泽布替尼、利妥昔单抗和高剂量甲氨蝶呤作为新诊断原发性中枢神经系统淋巴瘤的一线治疗（ZANA）：一项前瞻性、单臂研究讲者及单位：Zhizhou Xia，上海交通大学医学院附属瑞金医院摘要号：abs25-10677 英文标题：The phase II study of zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL) patients with specific gene-expression 中文标题：泽布替尼联合R-CHOP方案用于初治具有特定基因表达的弥漫大B细胞淋巴瘤（DLBCL）患者的Ⅱ期研究讲者及单位：Qunling Zhang，复旦大学附属肿瘤医院摘要号：abs25-7441 英文标题：Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL: A prospective biomarker study 中文标题：治疗中期的脑脊液循环肿瘤DNA (ctDNA) 和 MYD88 清除率在预测新诊断原发性中枢神经系统淋巴瘤 (PCNSL) 对奥布替尼为基础诱导治疗的反应和生存期方面优于 PET-CT：一项前瞻性生物标志物研究讲者及单位：Lixia Sheng，宁波大学附属第一医院摘要号：abs25-3826 英文标题：CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial 中文标题：CD19/CD22双特异性CAR-T细胞疗法治疗复发/难治性大B细胞淋巴瘤：一项前瞻性、单臂、单中心II期临床试验讲者及单位：王亮，首都医科大学附属北京同仁医院摘要号：abs25-2187 英文标题：Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile 中文标题：靶向CD19的CAR-T疗法治疗复发/难治性中枢神经系统淋巴瘤的前瞻性I/II期研究：临床结果和安全性特征讲者及单位：胡凯，北京高博医院摘要号：abs25-8684 英文标题：Efficacy of tgrx-678, a potent BCR::ABL1 allosteric inhibitor, in CML-CP and CML-AP patients harboring T315I mutation: Results from a phase 1 study 中文标题：TGRX-678（一种强效BCR::ABL1变构抑制剂）在携带T315I突变的慢性髓性白血病慢性期（CML-CP）和加速期（CML-AP）患者中的疗效：来自I期研究的结果讲者及单位：江倩，北京大学人民医院摘要号：abs25-8178 英文标题：Safety and efficacy of the JAK/rock inhibitor rovadicitinib in combination with the bromodomain and extra-terminal inhibitor TQB3617 in patients with myelofibrosis: A phase ib/II study 中文标题：JAK/ROCK抑制剂罗伐昔替尼联合溴结构域和末端外结构域抑制剂TQB3617治疗骨髓纤维化患者的安全性和有效性：一项Ib/II期研究讲者及单位：常春康，上海市第六人民医院摘要号：abs25-2492 英文标题：Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients 中文标题：一项IIb期、随机、活性对照研究的初步分析：Flonoltinib Maleate（FM）对比芦可替尼治疗中危-2或高危骨髓纤维化患者讲者及单位：牛挺，四川大学华西医院摘要号：abs25-4279 英文标题：Hetrombopag for the treatment of lower-risk myelodysplastic syndromes with thrombocytopenia: A prospective, single-arm, multicenter study 中文标题：海曲泊帕治疗低危骨髓增生异常综合征伴血小板减少症：一项前瞻性、单臂、多中心研究讲者及单位：Chen Mei，浙江大学医学院附属第一医院摘要号：abs25-13909 英文标题：Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton’s tyrosine kinase inhibitors (BTKis) 中文标题：Lisaftoclax 单药治疗对 Bruton 酪氨酸激酶抑制剂 (BTKis) 治疗失败的复发/难治性慢性淋巴细胞白血病/小淋巴细胞淋巴瘤 (CLL/SLL) 患者的治疗：一项注册性 II 期研究结果讲者及单位：周可树，河南省肿瘤医院摘要号：abs25-4169 英文标题：Mechanism of butyrate remodeled calcium signaling in NK cells reverses daratumumab resistance in multiple myeloma 中文标题：丁酸盐重塑NK细胞中的钙信号传导机制可逆转多发性骨髓瘤中对达雷妥尤单抗的耐药性讲者及单位：Tingting Li，重庆大学附属肿瘤医院摘要号：abs25-3972 英文标题：A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma 中文标题：评估LBL-034（一种以2:1比例靶向GPRC5D和CD3的条件激活双特异性抗体）治疗复发/难治性多发性骨髓瘤患者的首个人体、I/II 期、开放标签、多中心、剂量递增和扩展研究讲者及单位：路瑾，北京大学人民医院摘要号：abs25-10881 英文标题：Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma 中文标题：IBI3003（一种靶向GPRC5D、BCMA和CD3的新型三特异性抗体）在复发或难治性多发性骨髓瘤患者中的首次人体I期研究的初步结果讲者及单位：Jing Li，复旦大学附属中山医院摘要号：abs25-8596 英文标题：Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）中文标题：全人源 BCMA CAR-T 细胞疗法治疗高危新诊断不适合移植的多发性骨髓瘤的疗效与安全性：一项开放标签、单臂、I 期研究 (Fumanba-2) 的更新结果讲者及单位：Lijuan Chen，江苏省人民医院摘要号：abs25-4692 英文标题：BCMA CAR T-cell therapy in newly diagnosed primary plasma cell leukemia ineligible for transplantation: An open label, single-arm, phase 2 study (CAREMM-002) 中文标题：BCMA CAR-T 细胞疗法治疗不适合移植的新诊断原发性浆细胞白血病：一项开放标签、单臂、II 期研究 (CAREMM-002) 讲者及单位：Wenqiang Yan，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-13589 英文标题：Sequential BCMA and GPRC5D CAR-T cell therapy combined with an optimizing bridging regimen for Relapsed/Refractory multiple myeloma with bulky/extensive extramedullary disease: A synergistic integration approach 中文标题：序贯 BCMA 和 GPRC5D CAR-T 细胞疗法联合优化桥接方案治疗伴有巨大/广泛髓外病变的复发/难治性多发性骨髓瘤：一种协同整合策略讲者及单位：张亚晶，北京高博博仁医院摘要号：abs25-11105 英文标题：Combined biparatopic nanobody-based B cell maturation antigen chimeric antigen receptor T cell therapy and pomalidomide for relapsed or refractory multiple myeloma: In-vitro characterisation and phase 1 dose-escalation study 中文标题：双表位纳米抗体为基础的 B 细胞成熟抗原嵌合抗原受体 T 细胞疗法联合泊马度胺治疗复发或难治性多发性骨髓瘤：体外表征及 I 期剂量递增研究讲者及单位：隗佳，华中科技大学同济医学院附属同济医院摘要号：abs25-2764 英文标题：A dual targeting BCMA and CD19 fastcar-t (GC012F/AZD0120) as first-line therapy for newly diagnosed multiple myeloma 中文标题：双靶向 BCMA 和 CD19 的 FastCAR-T（GC012F/AZD0120）作为新诊断多发性骨髓瘤的一线治疗讲者及单位：杜鹃，上海长征医院摘要号：abs25-3841 英文标题：Single CAR-t infusion during front-line consolidation induces deep and sustained remission in newly diagnosed adult ph+b- ALL: A prospective phase 2 study 中文标题：单次CAR-T输注在新诊断的成人Ph+ B-ALL患者的一线巩固治疗中诱导深度且持久的缓解：一项前瞻性研究讲者及单位：顾闰夏，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-10603 英文标题：Tucidinostat plus R-CHOP in untreated MYC/BCL2 double-expressor diffuse large B-cell lymphoma topline efficacy and safety results from the randomized phase 3 DEB study 中文标题：西达本胺联合R-CHOP治疗未经治疗的MYC/BCL2双表达弥漫大B细胞淋巴瘤的随机3期DEB研究的前线疗效和安全性结果讲者及单位：赵维莅，上海交通大学医学院附属瑞金医院摘要号：abs25-8674 英文标题：Amlsp model for AML survival prediction 中文标题：AMLsp模型——用于急性髓系白血病生存预测的机器学习模型讲者及单位：Shasha Zhang，之江实验室生命科学计算研究中心摘要号：abs25-11039 英文标题：Bone marrow endothelial progenitor cells drive TKI resistance in CML via SEMA4D-plexinB1-mediated metabolic reprogramming 中文标题：骨髓内皮祖细胞通过SEMA4D-PlexinB1介导的代谢重编程驱动慢性髓系白血病对酪氨酸激酶抑制剂的耐药讲者及单位：Shunjie Yu，北京大学人民医院摘要号：abs25-9010 英文标题：Targeting PRMT7 enhances the anti-AML immunity by regulating MHC-I 中文标题：靶向PRMT7通过调控MHC-I增强抗急性髓系白血病（AML）免疫力讲者及单位：Shuaishuai Ge，苏州大学附属第一医院摘要号：abs25-10396 英文标题：Hematopoietic JAK2V617F mutation increases susceptibility to atrial fibrillation via NLRP3 inflammasome activation in macrophages 中文标题：造血JAK2V617F突变通过在巨噬细胞中激活NLRP3炎症体增加对房颤的易感性讲者及单位：Guangshuai Teng，天津医科大学第二医院摘要号：abs25-1948 英文标题：Macrophages mediate hematopoietic stem cell trans-endocytosis to coordinate regenerative stress and aging 中文标题：巨噬细胞介导造血干细胞的跨内吞作用，以协调再生应激和衰老讲者及单位：Zixuan Xu，上海交通大学医学院附属第九人民医院摘要号：abs25-9868 英文标题：Bone marrow adipocytes fuel hematopoietic regeneration via fatty acid release 中文标题：骨髓脂肪细胞通过释放脂肪酸促进造血再生讲者及单位：Xiang Gao，北京大学前沿交叉学科研究院非恶性血液疾病 ASH 2025 摘要号：abs25-8597 英文标题：A novel reduce toxity myeloablative conditioning regimen f-BMT improves efficacy and safety of allogeneic hematopoietic stem cell transplantation in patients with transfusion-dependent thalassemia: A multicenter clinical trial 中文标题：一种新型低毒性清髓性预处理方案f-BMT改善输血依赖型地中海贫血患者异基因造血干细胞移植的疗效和安全性：一项多中心临床试验讲者及单位：Xiaolin Yin，联勤保障部队第923医院摘要号： abs25-10516 英文标题：CFP1 controls H3K4me3-mediated chromatin architecture to promote v(D)j recombination in early B cell development 中文标题：CFP1通过调控H3K4me3介导的染色质结构来促进早期B细胞发育过程中的v(D)j重组讲者及单位：Wanyu Bai，中山大学附属第七医院摘要号：abs25-10042 英文标题：The selective JAK1 inhibitor upadacitinib restores impaired neutrophil chemotaxis in the proplatelet formation of immune thrombocytopenia 中文标题：选择性 JAK1 抑制剂Upadacitinib在免疫性血小板减少症的前血小板形成中恢复受损的中性粒细胞趋化性讲者及单位：Qiu-Sha Huang，北京大学人民医院摘要号：abs25-4368 英文标题：Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia 中文标题：ESLIM-01 3期研究：索乐匹尼布长期治疗慢性原发性免疫性血小板减少症成人患者的疗效和安全性最终分析讲者及单位：胡豫，华中科技大学同济医学院附属协和医院摘要号：abs25-2373 英文标题：Efficacy and safety results of linperlisib in adult patients with primary immune thrombocytopenia (ITP) 中文标题：林普利塞治疗成人原发性免疫性血小板减少症（ITP）的疗效和安全性结果讲者及单位：周虎，河南省肿瘤医院摘要号：abs25-1959 英文标题：Intermediate-dose (0.4 g/kg per Dose) versus standard high-dose (1.0 g/kg per Dose) intravenous immunoglobulin in pediatric primary immune thrombocytopenia: A multicenter randomized non-inferiority trial 中文标题：中等剂量（0.4 g/kg每次剂量）与标准高剂量（1.0 g/kg每次剂量）静脉免疫球蛋白治疗儿童原发性免疫性血小板减少症：一项多中心随机非劣效性试验讲者及单位：Yongzhi Zheng，福建医科大学附属协和医院摘要号：abs25-4670 英文标题：Efficacy and safety of NTQ5082 monotherapy in complement-inhibitor-Naïve patients with paroxysmal nocturnal hemoglobinuria: A proof-of-concept, multicenter, randomized, open-label phase 2 study 中文标题：NTQ5082单药治疗在补体抑制剂初治的阵发性睡眠性血红蛋白尿症患者中的疗效和安全性：一项概念验证、多中心、随机、开放标签的II期研究讲者及单位：张凤奎，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-10455 英文标题：LP-005, a bifunctional C5 antibody fusion protein, efficacy and safety in PNH patients with active hemolysis: Updated results from a Phase 2 study at 12/24 weeks 中文标题：LP-005，一种双功能C5抗体融合蛋白，在有活动性溶血的PNH患者中的疗效和安全性：来自12/24周的II期研究的更新结果讲者及单位：何广胜，江苏省人民医院摘要号：abs25-1574 英文标题：TADA1 plays a regulatory role in erythropoiesis and the expression of HBG 中文标题：TADA1在红细胞生成和HBG表达中发挥调节作用讲者及单位：Dawei Huo，浙江大学医学院附属第一医院摘要号：abs25-1450 英文标题：Baricitinib reveals LGALS3BP as a novel pathogenic factor and therapeutic target in immune thrombocytopenia 中文标题：巴瑞替尼揭示了LGALS3BP是免疫性血小板减少症的一种新的致病因子和治疗靶点讲者及单位：Kexin Shen，北京大学人民医院摘要号：abs25-2481 英文标题：Short-term fasting releases the hematopoietic brake to promote bone marrow erythropoiesis 中文标题：短期禁食释放造血“刹车”以促进骨髓红细胞生成讲者及单位：Wen Wei，苏州大学苏州医学院摘要号：abs25-11751 英文标题：Proof-of-concept study of the CD39-blocking antibody JS019 in eosinophilic-associateddisorde 中文标题：CD39阻断抗体JS019治疗嗜酸性粒细胞相关疾病的概念验证研究讲者及单位：Danqing Zhao，北京协和医院摘要号：abs25-4050 英文标题：Hypoxia-driven complement activation expands circulating endothelial cells in transplant associated thrombotic microangiopathy: A multi-omics single-cell and functional study 中文标题：缺氧驱动的补体激活在移植相关血栓性微血管病中外周血内皮细胞扩增的机制——基于多组学单细胞与功能研究讲者及单位：Jiaqian Qi，苏州大学第一附属医院摘要号：abs25-4714 英文标题：Curing Hemoglobin H-Constant Spring through Base Editing of Autologous CD34+ Hematopoietic Stem and Progenitor Cells 中文标题：通过碱基编辑技术纠正自体CD34⁺造血干/祖细胞，实现Hb H Constant Spring（Hb HCS）的治愈讲者及单位：Hui Xu，广州瑞风生物科技有限公司摘要号：abs25-9943 英文标题：A combinatorial caar-T cell strategy to eliminate factor VIII inhibitors in preclinical models of Hemophilia A 中文标题：基于组合式CAAR-T细胞技术在临床前模型中清除A型血友病的FVIII抑制物讲者及单位：Wenjie Li，中山大学附属第八医院摘要号：abs25-10452 英文标题：Efficacy and mechanism of BTK degrader nx-5948 in secondary hemophagocyticlymphohistiocytosis 中文标题：BTK降解剂NX-5948治疗继发性噬血细胞性淋巴组织细胞增多症的疗效与机制研究讲者及单位：Songtao Tu，江苏省人民医院摘要号：abs25-10767 英文标题：An unexpected role for maea in preventing ferroptosis of erythroblastic islandmacrophages to support erythropoiesis 中文标题：MAEA在防止成红细胞岛巨噬细胞铁死亡以支持红细胞生成中的意外作用讲者及单位：Xiaoli Qu，郑州大学摘要号：abs25-13085 英文标题：VSA012, a CFB-targeted siRNA, demonstrates a favorable safety profile and sustained efficacy in PNH patients: Interim Analysis from a Phase Ib Study 中文标题：VSA012（靶向CFB的小干扰RNA）在阵发性睡眠性血红蛋白尿（PNH）患者中展现出良好的安全性及持续疗效——来自一项Ib期研究的期中分析讲者及单位：Neng Nie，中国医学科学院血液病医院（中国医学科学院血液学研究所） CAR-T细胞疗法 ASH 2025 摘要号：abs25-8509 英文标题：Precision In Vivo CAR-T generation via CLAMP-enabled mRNA delivery: Toward scalable and translatable cell therapy 中文标题：CLAMP 介导的 mRNA 递送实现精准体内 CAR-T 生成：迈向可扩展且可转化的细胞疗法讲者及单位：Pin Wang，沙砾生物（Grit Biotechnology）摘要号：abs25-1754 英文标题：Modification of post-trogocytosis effects to Enhance CAR-t cell persistence 中文标题：修饰吞噬后效应以增强CAR-T细胞的持久性讲者及单位：Haotian Ma，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-10021 英文标题：Indoleamine 2,3-dioxygenase 1 (IDO1) promotes immune effector cell-associated neurotoxicity syndrome (ICANS) after CAR-T therapy by disrupting brain endothelial cell integrity via KYNU–AA–Wnt/β-catenin pathway 中文标题：吲哚胺2,3-双加氧酶1（IDO1）通过KYNU–AA–Wnt/β-catenin通路破坏脑内皮细胞完整性，促进CAR-T治疗后免疫效应细胞相关神经毒性综合征（ICANS）的发生讲者及单位：Wanying Zhang，华中科技大学同济医学院附属协和医院摘要号：abs25-4344 英文标题：CD7-targeted CAR-T cell therapy showed a high efficacy for 30 patients with relapsed or refractory central nervous system T-cell lymphoblastic leukemia/lymphoma 中文标题：靶向CD7的CAR-T细胞疗法对30例复发或难治性中枢神经系统T细胞急性淋巴细胞白血病/淋巴瘤患者显示较高的疗效讲者及单位：陆佩华，河北燕达陆道培医院摘要号：abs25-15341 英文标题：Interim Phase 1 study of sequential CD7 CAR T-cell therapy and haploidentical HSCT without GVHD prophylaxis in patients with Relapsed/Refractory CD7-positive hematologic malignancies 中文标题：复发/难治性CD7阳性血液恶性肿瘤患者接受序贯CD7 CAR-T细胞疗法和单倍体相合造血干细胞移植（HSCT）且不进行移植物抗宿主病（GVHD）预防的I期研究中期结果讲者及单位：Tingting Yang，浙江大学医学院附属第一医院摘要号：abs25-2883 英文标题：CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D) 中文标题：CTD402，异基因抗CD7 CAR-T细胞治疗复发或难治性（R/R）T细胞急性淋巴细胞白血病/淋巴母细胞淋巴瘤（T-ALL/LBL）——在推荐的II期剂量（RP2D）下的临床结果报告讲者及单位：陆佩华，河北燕达陆道培医院摘要号：abs25-2632 英文标题：CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies 中文标题：靶向CD7的通用CAR-T细胞疗法治疗复发或难治性（R/R）急性髓系白血病（AML）：CTD401/402研究的临床结果讲者及单位：胡永仙，浙江大学血液学研究所摘要号：abs25-2286 英文标题：A phase 1 study of lucar-G39D: A novel anti-CD20/CD19 dual-CAR allogeneic gamma delta T cells in adults with relapsed / refractory B-cell non-Hodgkin lymphoma (NHL) 中文标题：Lucar-G39D 的 I 期研究：一种新型抗 CD20/CD19 双 CAR 异基因 γδ T 细胞用于成人复发/难治性 B 细胞非霍奇金淋巴瘤 (NHL) 讲者及单位：Jingwei Yu，天津医科大学肿瘤医院摘要号：abs25-9994 英文标题：Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma 中文标题：IL-6敲低抗CD19的CAR-T细胞（ssCART-19）治疗原发性/继发性中枢神经系统淋巴瘤的安全性和有效性讲者及单位：Wenjun Zhang，同济大学附属同济医院摘要号：abs25-8180 英文标题：Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy 中文标题：设计免疫逃逸型UCAR-T细胞以克服异基因障碍并推进现货型免疫治疗讲者及单位：Luhan Yang，杭州启函生物科技有限公司异基因造血干细胞移植 ASH 2025 摘要号：abs25-9514 英文标题：Impacts of IPSS-m and conditioning intensity in allogeneic hematopoietic cell transplant for patients with myelodysplasia neoplasms 中文标题：IPSS-m和预处理强度在骨髓增生异常综合征患者异基因造血细胞移植中的影响讲者及单位：Zilu Zhang，上海交通大学医学院附属瑞金医院摘要号：abs25-9294 英文标题：Genomic clustering informs risk-adapted conditioning regimens in AML with pre-transplant deep remission: Augmented stratification beyond ELN-2022 criteria 中文标题：基因组聚类指导 AML 移植前深度缓解患者的个体化预处理方案：超越 ELN-2022 标准的增强分层讲者及单位：Ruixin Li，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-11017 英文标题：Analysis of efficacy and prognostic factors in transfusion-dependent thalassemia following allogeneic hematopoietic stem cell transplantation using the 'gx-07-tm' regimen 中文标题：采用“gx-07-tm”方案进行异基因造血干细胞移植治疗输血依赖型地中海贫血的疗效及预后因素分析讲者及单位：Hongwen Xiao，广西医科大学第一附属医院摘要号：abs25-9993 英文标题：High HLA evolutionary divergence mismatch increases the risk of acute graft-versus-host disease and mortality after haploidentical hematopoietic stem cell transplantation 中文标题：HLA进化差异高度不匹配会增加单倍体造血干细胞移植后发生急性移植物抗宿主病和死亡的风险讲者及单位：Ce Shi，浙江大学医学院附属第一医院骨髓移植中心摘要号：abs25-9824 英文标题：Metabolic reprogramming by itaconate: Haescs-derived therapy targets fibroblast GLUD1 to alleviate ocular graft versus host disease 中文标题：衣康酸介导的代谢重编程：源自Haescs的疗法靶向成纤维细胞GLUD1以缓解眼部移植物抗宿主病讲者及单位：Rui Ji，陆军军医大学新桥医院摘要号：abs25-11036 英文标题：Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis 中文标题：靶向 Hedgehog 信号通路/KL4 依赖性 M2 巨噬细胞极化治疗慢性移植物抗宿主病和组织纤维化讲者及单位：Yiping Yang，温州医科大学附属第一医院摘要号：abs25-14019 英文标题：Gut microbiota-related lithocholic acid alleviates cgvhd-induced bronchiolitis obliterans syndrome by suppressing CD4+ T cell TCR signaling without impairing the graft-versus-leukemia effect 中文标题：与肠道菌群相关的石胆酸通过抑制CD4+ T细胞TCR信号传导来缓解cGVHD诱导的闭塞性细支气管炎综合征，且不影响移植物抗白血病效应讲者及单位：Haowen Xiao，浙江大学医学院附属邵逸夫医院摘要号：abs25-11035 英文标题：Low-dose chidamide maintenance therapy following allogeneic hematopoietic stem cell transplantation in T-cell acute lymphoblastic leukemia or lymphoma: A phase 2, open-label, multicenter, single-arm trial 中文标题：异基因造血干细胞移植后低剂量西达本胺维持治疗T 细胞急性淋巴细胞白血病或淋巴瘤患者：一项 II 期、开放标签、多中心、单臂试验讲者及单位：Yi Yu，浙江大学医学院附属第一医院骨髓移植中心摘要号：abs25-4356 英文标题：Impact of hereditary predisposition genes to hematologic malignancies on transplant outcomes and donor selection 中文标题：遗传易感基因对血液系统恶性肿瘤移植结果和供体选择的影响讲者及单位：李智慧，北京高博博仁医院摘要号：abs25-7966 英文标题：Detection of minute FLT3-ITD clones at day +30 post-allo-HSCT predicts high relapse risk and informs maintenance therapy in AML: A niche cohort 中文标题：异基因造血干细胞移植后第30天检测到微小FLT3-ITD克隆可预测急性髓系白血病（AML）的高复发风险，并指导维持治疗：一项针对特定人群的研究讲者及单位：Shan Jiang，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-10488 英文标题：Monocyte-T cells crosstalk orchestrates early graft-versus-leukemia immunity in Acute Myeloid Leukemia patients after allogeneic transplantation 中文标题：单核细胞-T细胞相互作用在急性髓系白血病患者异基因移植后早期发挥移植物抗白血病免疫反应讲者及单位：Weiqian Dai，中国医学科学院血液病医院（中国医学科学院血液学研究所）摘要号：abs25-2491 英文标题：Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT 中文标题：对于达到完全缓解但可检测到微小残留病（MRD）的成人急性髓系白血病（AML）患者，单倍体相合供体比同胞全相合供体的异基因移植效果更好：欧洲骨髓移植学会（EBMT）全球委员会和急性白血病工作组（ALWP）的研究讲者及单位：叶逸山，浙江大学医学院附属第一医院血液骨髓移植中心摘要号：abs25-9947 英文标题：Azacitidine combined with Venetoclax for pre-emptive treatment of AML/MDS after allogeneic stem cell transplantation: A prospective phase II study 中文标题：阿扎胞苷联合维奈克拉用于异基因干细胞移植后急性髓系白血病/骨髓增生异常综合征（AML/MDS）的抢先治疗：一项前瞻性II期研究讲者及单位：Lizhen Liu，浙江大学医学院附属第一医院血液骨髓移植中心摘要号：abs25-11470 英文标题：Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial 中文标题：阿伐曲泊帕改善单倍体造血干细胞移植后血小板植入——一项随机、双盲、多中心、安慰剂对照临床试验讲者及单位：Hai-Xia Fu，北京大学人民医院摘要号：abs25-9466 英文标题：Prognostic impact of donor KIR genotypes on clinical outcomes in pediatric allogeneic hematopoietic stem cell transplantation 中文标题：供者杀伤细胞免疫球蛋白样受体（KIR）基因型对儿童异基因造血干细胞移植（allo-HSCT）临床结局的影响讲者及单位：Uet Yu，上海交通大学附属儿童医院新兴工具、技术和人工智能 ASH 2025 摘要号：abs25-11144 英文标题：An AI-driven biomarker signature for prognostic risk stratification in transplant-associated thrombotic microangiopathy - a nationwide, multicenter study 中文标题：移植相关性血栓性微血管病变预后风险分层的 AI 驱动生物标志物特征：一项全国性、多中心研究讲者及单位：安倬玉，北京大学人民医院摘要号：abs25-10902 英文标题：The total blood n-glycome landscape of hematological malignancies 中文标题：血液恶性肿瘤的总N-糖组全景讲者及单位：陈兵，南京大学医学院附属鼓楼医院摘要号：abs25-9918 英文标题：Discrimination of Epstein–Barr virus latent infection and lytic replication reactivation using a novel methyl-CRISPR biosensor 中文标题：利用一种新型甲基化CRISPR生物传感器区分Epstein-Barr病毒的潜伏感染和裂解复制再激活讲者及单位：Ting Wang，北京大学人民医院摘要号：abs25-8764 英文标题：Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy 中文标题：基于序列信息的人工智能导向抑制性肽段在基因治疗中拮抗AAV中和抗体的研究讲者及单位：Bingqi Xu，中国医学科学院血液病医院（中国医学科学院血液学研究所）温馨提示本文呈现了讲者单位所属地为中国的研究，如有遗漏或任何问题，请与我们联系或留言~ （来源：《肿瘤瞭望–血液时讯》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床1期突破性疗法

2025-11-04

·GlobeNewswire-Health Care

ORYZON Announces Positive Clinical Data of Iadademstat at ASH-2025

Three iadademstat abstracts have been accepted for presentation at the upcoming ASH-2025 Annual MeetingPreliminary data from the ongoing Phase Ib trial combining iadademstat with azacitidine and venetoclax in newly diagnosed, unfit AML patients showed a 100% overall response rateUpdated preliminary data from the ongoing Phase Ib FRIDA trial evaluating iadademstat in combination with gilteritinib in FLT3-mutated relapsed/refractory AML showed a 67% response rate in the expanded dose, superior to both historical and real-world gilteritinib monotherapy MADRID and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that three abstracts featuring iadademstat, its selective LSD1 inhibitor for onco-hematology, have been accepted for presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6-9, 2025, in Orlando, Florida (USA). The accepted abstracts highlight encouraging clinical activity and safety data from two ongoing clinical studies evaluating iadademstat-based combinations in patients with acute myeloid leukemia (AML): the company-sponsored FRIDA study in FLT3-mutant relapsed/refractory AML in combination with gilteritinib, and an investigator-initiated study sponsored by Oregon Health & Science University (OHSU) in first line unfit AML setting in combination with venetoclax-azacitidine. In addition, a Trial-in-progress (TIP) abstract has been accepted relating to a new randomized study of iadademstat in combination with ASTX727 in advanced myeloproliferative neoplasms (MPNs), sponsored by the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) that Oryzon has in place with the NCI. A TIP abstract is a brief summary that describes the design, objectives, and status of an ongoing clinical trial, without reporting results. Dr. Ana Limón, Senior Vice President of Clinical Development and Medical Affairs at Oryzon, said: “The emerging data from these AML studies, which demonstrate that adding iadademstat to the current standards of care—venetoclax plus azacitidine in treatment-naïve AML patients, or plus gilteritinib in relapsed/refractory FLT3-mutated AML—enhances efficacy without increasing toxicity, is very encouraging. This finding is particularly noteworthy in the FLT3+ R/R population, as 42% of patients in our cohort had been previously treated with venetoclax, a group known to exhibit poor responses to gilteritinib monotherapy and therefore in urgent need of better therapies. We are also excited to see emergent trials with iadademstat combinations in myeloid malignancies other than AML that are in need of new therapies, including MDS and MPNs, the latter featured in the NCI’s TIP”. “We are very pleased that these iadademstat abstracts have been selected for presentation at ASH 2025,” said Dr. Carlos Buesa, Chief Executive Officer of Oryzon. "The results to be presented are very promising and underscore iadademstat’s potential as a potent and versatile epigenetic modulator in AML, capable of synergizing with existing standard-of-care regimens to achieve responses in difficult-to-treat populations, with good tolerability.” Summary of Accepted Abstracts Abstract Title: Preliminary safety and efficacy data of the FRIDA study: iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia Presenting Author: Dr. Amir FathiType: Poster PresentationSession Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster IIISession Date: December 8, 2025Presentation Time: 6:00 PM - 8:00 PM ESTRoom: OCCC - West Halls B3-B4Presentation ID: 5197 The Phase Ib FRIDA study (NCT05546580) is evaluating the safety, tolerability and recommended Phase 2 dose (RP2D) of the combination of iadademstat plus gilteritinib in FLT3-mutated relapsed or refractory AML. At the time of abstract submission, 34 patients had been enrolled, with 4 dose level cohorts evaluated in the escalation phase. The combination is tolerable at the tested doses. The study is in the expansion phase at one selected pharmacologically active dose, with a total of 14 patients enrolled in the study at this dose level. At the selected dose for expansion, the combination shows a 67% response rate (8/12 patients) and a 58% complete response rate (CR+CRh+CRi, 7/12 patients) in the 12 evaluable patients. Three patients have undergone HSCT. Updated data will be presented at the congress. Abstract Title: Preliminary safety and efficacy results of a Phase Ib investigation of the LSD1 inhibitor iadademstat (ORY-1001) in combination with azacitidine and venetoclax in newly-diagnosed AML Presenting Author: Dr. Curtis LachowiezType: Poster PresentationSession Name: 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: Poster ISession Date: December 6, 2025Presentation Time: 5:30 PM - 7:30 PM ESTRoom: OCCC - West Halls B3-B4Presentation ID: 1649 This Phase Ib trial (NCT06357182) evaluates iadademstat in combination with azacitidine and venetoclax in patients with newly diagnosed AML. Preliminary data from the first 8 patients enrolled show the triplet combination is safe and active, resulting in high response rates. The overall response rate (ORR) was 100% (n=8), with 88% achieving complete remission (CR), and 12.5% morphologic leukemia-free state (MLFS). After a median follow-up of 9 months, the estimated 6‑month overall survival (OS) was 88%. No dose-limiting toxicities were observed. Abstract Title: Trial in progress - a randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase myeloproliferative neoplasms Presenting Author: Dr. Anand PatelType: Poster PresentationSession Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster IISession Date: December 7, 2025Presentation Time: 6:00 PM - 8:00 PM ESTRoom: OCCC - West Halls B3-B4Presentation ID: 3827 This Phase II study (NCT06661915) is investigating ASTX727 (oral decitabine and cedazuridine) with or without iadademstat in treating patients with accelerated/blast phase myeloproliferative neoplasms (MPN-AP/BP). The study has a dose escalation phase to identify the recommended phase 2 dose (R2PD) of iadademstat + ASTX727, followed by a randomized phase which will investigate the efficacy of iadademstat + ASTX727 compared to ASTX727 monotherapy. The dose escalation phase will follow a 3+3 design. The randomization will be 1:1 with 25 patients treated on each arm during the randomized portion. The primary endpoint will be the rate of acute leukemia response-complete (ALR-C) or better within 4 cycles of therapy. An interim analysis for futility will be performed after 25 patients are enrolled and followed for ALR-C. This study is sponsored and conducted by the NCI, and recently started to enroll patients. There is a critical need for new treatments for patients with MPNs, specially for those in accelerated phase (AP) or blast phase (BP), as current therapeutic options yield poor survival outcomes of just 3-5 months in BP and 12-18 months in AP. Available treatments, outside allogeneic hematopoietic cell transplantation, which remains the only potentially curative intervention, rarely induce durable disease modification or clonal clearance. Disease modification, rather than solely symptom relief, is a unique appeal of LSD1 inhibitors in MPN—by targeting both the underlying malignant clone as well as fibrosis and cytokine-driven complications. The abstracts are available online on ASH website at www.hematology.org. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com About IadademstatIadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (see Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A FiM Phase I/IIa clinical trial with iadademstat in R/R AML patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi (see Salamero et al, J Clin Oncol, 2020, 38(36): 4260-4273. doi: 10.1200/JCO.19.03250). Iadademstat has shown encouraging safety and strong clinical activity in combination with azacitidine in a Phase IIa trial in elder 1L AML patients (ALICE trial) (see Salamero et al., ASH 2022 oral presentation & The Lancet Haematology, 2024, 11(7):e487-e498). Iadademstat is currently being evaluated in combination with gilteritinib in the ongoing Phase Ib FRIDA trial in patients with relapsed/refractory AML with FLT3 mutations, and in combination with azacitidine and venetoclax in 1L AML in an investigator-initiated study led by OHSU and in a trial sponsored by the U.S. National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) signed between Oryzon and the NCI to collaborate on further clinical development of iadademstat in different types of hematologic and solid cancers. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), neuroendocrine tumors (NET), medulloblastoma and others. In a Phase IIa trial in combination with platinum/etoposide in second line ED-SCLC patients (CLEPSIDRA trial), preliminary activity and safety results have been reported (see Navarro et al., ESMO 2018 poster). Iadademstat is in a Phase I/II randomized trial in 1L ED-SCLC in combination with ICI sponsored by NCI and led by the Memorial Sloan Kettering Cancer Center. Oryzon is further expanding the clinical development of iadademstat in oncology through additional CRADA and investigator-initiated studies. In addition, Oryzon is expanding iadademstat’s clinical development into non-oncological hematology indications, with trials in sickle cell disease (enrolling) and essential thrombocythemia (trial in preparation). Iadademstat has orphan drug designation for SCLC in the US and for AML in the US and EU. FORWARD-LOOKING STATEMENTS This communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration. SpainOryzonIR & Media, Europe & USPatricia Cobo/Mario CorderaEmili TorrellSandya von der WeidAtreviaChief BD OfficerLifeSci Advisors, LLC+34 91 564 07 25+34 673 33 97 65+34 93 515 1313+41 78 680 05 38pcobo@atrevia.commcordera@atrevia.cometorrell@oryzon.comsvonderweid@lifesciadvisors.com

临床1期临床结果临床2期ASH会议细胞疗法

100 项与阿扎胞苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D03021	阿扎胞苷	L01BC07	DB00928

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
幼年型骨髓单核细胞白血病	美国	Bristol Myers Squibb Co.	2022-05-20
骨髓增生性疾病	欧盟	betapharm Arzneimittel GmbH	2020-03-24
骨髓增生性疾病	冰岛	betapharm Arzneimittel GmbH	2020-03-24
骨髓增生性疾病	列支敦士登	betapharm Arzneimittel GmbH	2020-03-24
骨髓增生性疾病	挪威	betapharm Arzneimittel GmbH	2020-03-24
费城染色体阳性慢性粒细胞白血病	中国	Bristol-Myers Squibb Pharma EEIG	2017-04-24
高危骨髓增生异常综合征	澳大利亚	Celgene Pty Ltd.	2009-11-30
急性髓性白血病	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-12-17
急性髓性白血病	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-12-17
急性髓性白血病	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-12-17
急性髓性白血病	挪威	Bristol-Myers Squibb Pharma EEIG	2008-12-17
慢性粒单核细胞白血病	欧盟	Bristol-Myers Squibb Pharma EEIG	2008-12-17
慢性粒单核细胞白血病	冰岛	Bristol-Myers Squibb Pharma EEIG	2008-12-17
慢性粒单核细胞白血病	列支敦士登	Bristol-Myers Squibb Pharma EEIG	2008-12-17
慢性粒单核细胞白血病	挪威	Bristol-Myers Squibb Pharma EEIG	2008-12-17
骨髓增生异常综合征	美国	Bristol Myers Squibb Co.	2004-05-19

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫母细胞性淋巴结病	临床3期	日本	Celgene Corp.	2018-11-06
血小板减少症	临床3期	美国	Celgene Corp.	2013-04-26
血小板减少症	临床3期	澳大利亚	Celgene Corp.	2013-04-26
血小板减少症	临床3期	比利时	Celgene Corp.	2013-04-26
血小板减少症	临床3期	巴西	Celgene Corp.	2013-04-26
血小板减少症	临床3期	加拿大	Celgene Corp.	2013-04-26
血小板减少症	临床3期	捷克	Celgene Corp.	2013-04-26
血小板减少症	临床3期	丹麦	Celgene Corp.	2013-04-26
血小板减少症	临床3期	芬兰	Celgene Corp.	2013-04-26
血小板减少症	临床3期	法国	Celgene Corp.	2013-04-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04372433 (Pubmed \| Blood Neoplasia)	临床1期	急性髓性白血病 \| 慢性粒单核细胞白血病	18	IO-202 + azacitidine	憲製夢構繭醖選網鏇蓋(淵繭窪顧網齋淵鑰鏇鬱) = 鹽艱齋窪廠壓夢蓋壓淵繭齋憲選簾夢膚鏇鹹襯 (憲築繭淵範廠鏇製夢遞 ) 更多	积极	2025-11-01
NCT05428969 (BEXMAB, ESMO2025)	临床1/2期	骨髓增生异常综合征一线	52	bexmarilimab + azacitidine (frontline HR MDS)	壓壓餘餘夢鑰醖鏇遞鬱(蓋餘鹹築鹽憲觸鬱觸觸) = 25% increase of BM CD8+ T cells, already after cycle 1 鑰糧糧醖壓選窪範憲築 (淵製鹹鑰膚繭壓齋願選 ) 更多	积极	2025-10-17
				bexmarilimab + azacitidine (relapsed/refractory (r/r) MDS)
NCT04102020 (VIALE-M, CTgov)	临床3期	急性髓性白血病	112	Venetoclax+Azacitidine (Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2)	製獵窪鏇構選築選衊艱 = 遞願簾蓋襯顧齋鬱構膚憲顧衊製願築製鹹顧繭 (夢獵繭淵願蓋鹹窪艱觸, 鹽願糧觸範膚廠鑰襯膚 ~ 遞膚衊鏇製糧廠遞繭簾) 更多	-	2025-08-20
				Venetoclax+Azacitidine (Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2)	製獵窪鏇構選築選衊艱 = 糧壓壓製顧憲憲蓋憲衊憲顧衊製願築製鹹顧繭 (夢獵繭淵願蓋鹹窪艱觸, 鹹齋鹹觸觸鹽鹽簾願襯 ~ 鑰網鬱壓窪選壓遞廠憲) 更多
NCT03013998 (Pubmed \| J Clin Oncol)	临床1期	难治性急性髓细胞白血病 NPM1m \| KMT2Ar	43	Azacitidine, Venetoclax, and Revumenib	繭選繭艱觸獵製構壓築(鏇窪壓膚糧築鹽淵夢構) = present in 8 (19%) patients 窪積觸網鹹夢築鹽簾壓 (鬱繭鏇鹽餘獵獵選鑰餘 ) 更多	积极	2025-08-10
NCT02269280 (PF629, CTgov)	临床2期	慢性粒单核细胞白血病 \| 白血病 \| 骨髓增生异常综合征	185	AZA+Azacitidine (Azacitidine (AZA) - Days 1 - 3)	網蓋蓋餘鑰簾艱窪夢鏇(積積築廠鹹鏇簾範蓋網) = 廠壓願鑰蓋壓蓋選鹽遞鏇衊遞襯齋觸觸廠糧遞 (廠餘範膚壓窪醖範鏇簾, 醖鬱簾糧襯糧鹹蓋齋獵 ~ 獵齋繭窪糧簾鬱觸築廠) 更多	-	2025-08-07
				Azacitidine (AZA) Days 1 - 5 (Azacitidine (AZA) - Days 1 - 5)	網蓋蓋餘鑰簾艱窪夢鏇(積積築廠鹹鏇簾範蓋網) = 鏇築餘遞繭窪積積齋觸鏇衊遞襯齋觸觸廠糧遞 (廠餘範膚壓窪醖範鏇簾, 窪艱鹹願顧範淵艱觸遞 ~ 鏇築範鑰製獵齋網窪鹽) 更多
NCT05209152 (MDS-537, CTgov)	临床1期	高危骨髓增生异常综合征 \| 慢性粒单核细胞白血病	7	AMG 176 (Part 1A Dose Exploration: AMG 176 Dose Level 1)	鹹憲鬱範鏇鹽鹽鹽範壓 = 遞簾鹽選鹹簾網鑰醖膚築夢艱淵築鑰積積鏇膚 (鬱鬱獵淵衊廠餘衊遞積, 窪築構餘鬱鹽鹹衊積衊 ~ 蓋築製築鏇蓋膚膚觸餘) 更多	-	2025-07-14
				AMG 176 (Part 1A Dose Exploration: AMG 176 Dose Level 1 Then Dose Level 2)	鹹憲鬱範鏇鹽鹽鹽範壓 = 窪願淵獵鏇選醖積憲壓築夢艱淵築鑰積積鏇膚 (鬱鬱獵淵衊廠餘衊遞積, 夢繭淵顧壓獵鑰製襯選 ~ 構繭夢鬱衊積糧夢鑰鑰) 更多
Pubmed \| Ther Adv Hematol	临床2期	复发性弥漫性大B细胞淋巴瘤	15	Azacitidine + R-GDP	製艱衊衊襯淵淵淵憲壓(鹹夢製鑰鬱積餘遞選齋) = 糧醖襯夢網鬱衊壓蓋蓋製襯遞壓醖齋鹽願餘鹽 (夢憲鹽鏇積壓襯繭簾鹽 ) 更多	积极	2025-07-01
EHA2025 人工标引	N/A	外周T细胞淋巴瘤	14	Linperlisib + Azacitidine	鏇憲蓋繭壓顧鏇蓋襯願(鬱顧網積鬱遞夢選鬱襯) = 顧鑰願壓衊繭糧獵醖艱顧襯壓築願範齋鏇繭繭 (窪遞鬱壓淵襯築膚憲衊 ) 更多	积极	2025-06-12
NCT03850574 (APTIVATE \| TUSCANY, GlobeNewswire) 人工标引	临床1/2期	急性髓性白血病一线 TP53 \| CKB \| FLT3	10	TUS(40mg)+VEN+AZA	夢淵夢範鑰鹹鹽壓鹹襯(蓋築淵淵顧鹽窪鏇糧鬱) = 製襯鏇鬱構範膚鹹夢鹽膚鹹觸醖艱簾構鑰遞壓 (襯鹹積顧窪繭鑰餘繭窪 )	积极	2025-06-12
				TUS(80mg)+VEN+AZA	夢淵夢範鑰鹹鹽壓鹹襯(蓋築淵淵顧鹽窪鏇糧鬱) = 願鬱鹹膚製餘鬱醖憲憲膚鹹觸醖艱簾構鑰遞壓 (襯鹹積顧窪繭鑰餘繭窪 )
NCT00629343 (CTgov)	临床1期	恶性间皮瘤 \| 软组织肉瘤	27	Temozolomide+Azacitidine	積願壓鏇網鏇鑰醖壓醖 = 簾膚襯廠鬱醖醖艱獵憲繭醖鏇齋鑰醖膚構遞繭 (齋遞鹹鏇築衊艱鑰鑰壓, 觸鹽顧積鏇廠築廠遞簾 ~ 壓襯膚簾築膚網鑰鹽網) 更多	-	2025-06-05